JPWO2019136309A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019136309A5 JPWO2019136309A5 JP2020557125A JP2020557125A JPWO2019136309A5 JP WO2019136309 A5 JPWO2019136309 A5 JP WO2019136309A5 JP 2020557125 A JP2020557125 A JP 2020557125A JP 2020557125 A JP2020557125 A JP 2020557125A JP WO2019136309 A5 JPWO2019136309 A5 JP WO2019136309A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- human
- set forth
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090001123 antibodies Proteins 0.000 claims description 1397
- 102000004965 antibodies Human genes 0.000 claims description 1397
- 108010000499 Thromboplastin Proteins 0.000 claims description 748
- 102000002262 Thromboplastin Human genes 0.000 claims description 748
- 230000027455 binding Effects 0.000 claims description 423
- 125000000539 amino acid group Chemical group 0.000 claims description 322
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims description 271
- 108090000190 Thrombin Proteins 0.000 claims description 271
- 229960004072 thrombin Drugs 0.000 claims description 271
- 238000004519 manufacturing process Methods 0.000 claims description 250
- 238000004166 bioassay Methods 0.000 claims description 232
- 239000000611 antibody drug conjugate Substances 0.000 claims description 210
- 108091008116 antibody drug conjugates Proteins 0.000 claims description 210
- 238000003260 fluorescence intensity Methods 0.000 claims description 125
- 238000010186 staining Methods 0.000 claims description 125
- 241000700159 Rattus Species 0.000 claims description 112
- 230000035772 mutation Effects 0.000 claims description 91
- 229960003766 Thrombin (Human) Drugs 0.000 claims description 79
- 201000011510 cancer Diseases 0.000 claims description 75
- 239000002254 cytotoxic agent Substances 0.000 claims description 31
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 31
- 241000282567 Macaca fascicularis Species 0.000 claims description 26
- 230000001419 dependent Effects 0.000 claims description 25
- 201000010099 disease Diseases 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 24
- 230000011664 signaling Effects 0.000 claims description 22
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 14
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims description 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 14
- 229920000023 polynucleotide Polymers 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 241000282898 Sus scrofa Species 0.000 claims description 11
- 206010064930 Age-related macular degeneration Diseases 0.000 claims description 10
- 208000002780 Macular Degeneration Diseases 0.000 claims description 10
- 102200153680 NUSAP1 K68N Human genes 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000006011 modification reaction Methods 0.000 claims description 9
- 230000033115 angiogenesis Effects 0.000 claims description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010017758 Gastric cancer Diseases 0.000 claims description 7
- 208000005017 Glioblastoma Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010025650 Malignant melanoma Diseases 0.000 claims description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 206010038389 Renal cancer Diseases 0.000 claims description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 102000015694 estrogen receptors Human genes 0.000 claims description 7
- 108010038795 estrogen receptors Proteins 0.000 claims description 7
- 201000010536 head and neck cancer Diseases 0.000 claims description 7
- 201000010982 kidney cancer Diseases 0.000 claims description 7
- 230000003902 lesions Effects 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 102000003998 progesterone receptors Human genes 0.000 claims description 7
- 108090000468 progesterone receptors Proteins 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 7
- 230000035693 Fab Effects 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 229940079593 drugs Drugs 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 206010047116 Vascular inflammations Diseases 0.000 claims description 5
- 108091006028 chimera Proteins 0.000 claims description 5
- 230000001575 pathological Effects 0.000 claims description 5
- HMQPEDMEOBLSQB-UITYFYQISA-N β-D-Galp-(1->3)-D-GalpNAc Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HMQPEDMEOBLSQB-UITYFYQISA-N 0.000 claims description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 4
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims description 4
- 229960004562 Carboplatin Drugs 0.000 claims description 4
- 229960004679 Doxorubicin Drugs 0.000 claims description 4
- 229940088597 Hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 230000036499 Half live Effects 0.000 claims description 3
- 230000001413 cellular Effects 0.000 claims description 3
- 230000000295 complement Effects 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 3
- 239000000546 pharmaceutic aid Substances 0.000 claims description 3
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 2
- 206010059512 Apoptosis Diseases 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 2
- 229960000684 Cytarabine Drugs 0.000 claims description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000640 Dactinomycin Drugs 0.000 claims description 2
- 108010092160 Dactinomycin Proteins 0.000 claims description 2
- 229960000975 Daunorubicin Drugs 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229940088598 Enzyme Drugs 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 Etoposide Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 230000036740 Metabolism Effects 0.000 claims description 2
- 108091005771 Peptidases Proteins 0.000 claims description 2
- 102000035443 Peptidases Human genes 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- 231100000765 Toxin Toxicity 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229930013930 alkaloids Natural products 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims description 2
- 230000003042 antagnostic Effects 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000038129 antigens Human genes 0.000 claims description 2
- 108091007172 antigens Proteins 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- -1 camptothecan Chemical compound 0.000 claims description 2
- 150000002019 disulfides Chemical class 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 239000003667 hormone antagonist Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000035786 metabolism Effects 0.000 claims description 2
- 230000000394 mitotic Effects 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrugs Drugs 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 230000002285 radioactive Effects 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- OMJKFYKNWZZKTK-UHFFFAOYSA-N 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)NN=C1N=CN=C1C(N)=O OMJKFYKNWZZKTK-UHFFFAOYSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229960000908 Idarubicin Drugs 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- 208000001083 Kidney Disease Diseases 0.000 claims 1
- 101710037934 QRSL1 Proteins 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 16
- 230000000977 initiatory Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023110621A JP2023134565A (ja) | 2018-01-04 | 2023-07-05 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| JP2023142243A JP2023175726A (ja) | 2018-01-04 | 2023-09-01 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862613545P | 2018-01-04 | 2018-01-04 | |
| US201862613564P | 2018-01-04 | 2018-01-04 | |
| US62/613,564 | 2018-01-04 | ||
| US62/613,545 | 2018-01-04 | ||
| US201862646788P | 2018-03-22 | 2018-03-22 | |
| US62/646,788 | 2018-03-22 | ||
| US201862713797P | 2018-08-02 | 2018-08-02 | |
| US201862713804P | 2018-08-02 | 2018-08-02 | |
| US62/713,804 | 2018-08-02 | ||
| US62/713,797 | 2018-08-02 | ||
| PCT/US2019/012427 WO2019136309A1 (fr) | 2018-01-04 | 2019-01-04 | Anticorps anti-facteur tissulaire, conjugués anticorps-médicament et procédés associés |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110621A Division JP2023134565A (ja) | 2018-01-04 | 2023-07-05 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021509823A JP2021509823A (ja) | 2021-04-08 |
| JPWO2019136309A5 true JPWO2019136309A5 (fr) | 2022-01-13 |
Family
ID=67143785
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020557125A Pending JP2021509823A (ja) | 2018-01-04 | 2019-01-04 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| JP2023110621A Pending JP2023134565A (ja) | 2018-01-04 | 2023-07-05 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| JP2023142243A Pending JP2023175726A (ja) | 2018-01-04 | 2023-09-01 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023110621A Pending JP2023134565A (ja) | 2018-01-04 | 2023-07-05 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
| JP2023142243A Pending JP2023175726A (ja) | 2018-01-04 | 2023-09-01 | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20220153871A1 (fr) |
| EP (1) | EP3735271A4 (fr) |
| JP (3) | JP2021509823A (fr) |
| KR (1) | KR20200118029A (fr) |
| CN (1) | CN111818943A (fr) |
| AU (1) | AU2019205330A1 (fr) |
| BR (1) | BR112020013679A2 (fr) |
| CA (1) | CA3087537A1 (fr) |
| IL (1) | IL275765A (fr) |
| MX (1) | MX2020007077A (fr) |
| PH (1) | PH12020551037A1 (fr) |
| SG (1) | SG11202006400UA (fr) |
| WO (1) | WO2019136309A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818943A (zh) | 2018-01-04 | 2020-10-23 | 伊科尼克治疗公司 | 抗组织因子抗体、抗体-药物缀合物及相关方法 |
| BR112021001691A2 (pt) * | 2018-08-16 | 2021-05-04 | Genmab A/S | método de tratamento de câncer de ovário, câncer peritoneal ou câncer de trompa de falópio, e, kit |
| AU2020299398A1 (en) * | 2019-07-03 | 2022-02-24 | Iconic Therapeutics Llc | Anti-tissue factor antibody-drug conjugates and related methods |
| TW202200618A (zh) * | 2020-03-17 | 2022-01-01 | 美商西雅圖免疫公司 | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 |
| JPWO2021200131A1 (fr) * | 2020-03-30 | 2021-10-07 | ||
| JP2023534191A (ja) * | 2020-07-10 | 2023-08-08 | アイコニック セラピューティクス インコーポレイテッド | 抗組織因子抗体を使用する炎症性疾患の治療法 |
| TW202345906A (zh) * | 2022-03-09 | 2023-12-01 | 美商艾克塞里克斯公司 | 以抗組織因子抗體藥物結合物治療實體腫瘤之方法 |
| WO2024054821A2 (fr) * | 2022-09-07 | 2024-03-14 | Exelixis, Inc. | Conjugués anticorps-médicament de facteur tissulaire et leurs utilisations |
Family Cites Families (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| AU625013B2 (en) | 1989-11-03 | 1992-06-25 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| IL97459A0 (en) | 1990-03-09 | 1992-06-21 | Hybritech Inc | Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US6037135A (en) | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| US5662907A (en) | 1992-08-07 | 1997-09-02 | Cytel Corporation | Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes |
| AU5093593A (en) * | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
| US6413935B1 (en) | 1993-09-14 | 2002-07-02 | Epimmune Inc. | Induction of immune response against desired determinants |
| JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン，インコーポレイティド | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5837484A (en) | 1993-11-09 | 1998-11-17 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
| EP0787200B1 (fr) | 1994-10-28 | 2005-04-20 | The Trustees Of The University Of Pennsylvania | Adenovirus ameliore et ses procedes d'utilisation |
| FR2726285B1 (fr) | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| WO1998000110A1 (fr) | 1996-07-03 | 1998-01-08 | University Of Pittsburgh | Formulations d'emulsions pour des agents actifs hydrophiles |
| WO1998010087A1 (fr) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Vecteurs d'adenovirus de chimpanze |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US5849561A (en) | 1997-05-22 | 1998-12-15 | Cornell Research Foundation, Inc. | Method for the production of non-group C adenoviral vectors |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| IL138801A0 (en) * | 1998-04-03 | 2001-10-31 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor and process for the preparation thereof |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| US20080050393A1 (en) | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
| CA2354374A1 (fr) | 1998-12-07 | 2000-06-15 | U.S. Medical Research Institute Of Infectious Diseases | Vaccin vivant attenue de l'encephalomyelite equine du venezuela |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| WO2000061770A2 (fr) | 1999-04-08 | 2000-10-19 | Chiron Corporation | Stimulation de la reponse immune pour applications dans des vaccins et en therapie genique |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| CA2373300C (fr) | 1999-04-14 | 2012-02-21 | Chiron Corporation | Compositions et procedes permettant de generer une reponse immunitaire au moyen de systemes de vecteurs a base d'alphavirus |
| US6365394B1 (en) | 1999-09-29 | 2002-04-02 | The Trustees Of The University Of Pennsylvania | Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus |
| US6703494B2 (en) * | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| AU2001252945A1 (en) | 2000-03-24 | 2001-10-08 | Corixa Corporation | Compositions and methods for therapy and diagnosis of colon cancer |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20040115625A1 (en) | 2000-10-02 | 2004-06-17 | Reinhard Ebner | Cancer gene determination and therapeutic screening using signature gene sets |
| US6783939B2 (en) | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| AU2001291162A1 (en) | 2000-09-25 | 2002-04-08 | Regents Of The University Of Michigan | Production of viral vectors |
| PT2316940E (pt) | 2000-12-18 | 2013-10-16 | Dyax Corp | Bibliotecas orientadas de pacotes genéticos |
| US20020137081A1 (en) | 2001-01-08 | 2002-09-26 | Olga Bandman | Genes differentially expressed in vascular tissue activation |
| EP1363660A4 (fr) | 2001-02-01 | 2006-06-21 | Univ Johns Hopkins | Vaccin moleculaire superieur a base d'arn autoreplicatif, d'adn suicide ou de vecteur d'adn nu, qui lie un antigene a un polypeptide qui favorise la presentation de l'antigene |
| US20030232324A1 (en) | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| EP1399183B1 (fr) | 2001-05-31 | 2010-06-30 | Novartis Vaccines and Diagnostics, Inc. | Particules de replicon d'alphavirus chimerique |
| AU2002322285A1 (en) | 2001-06-22 | 2003-01-08 | The Trustees Of The University Of Pennsylvania | Method for rapid screening of bacterial transformants and novel simian adenovirus proteins |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| US7285265B2 (en) | 2002-04-25 | 2007-10-23 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| GB2398300A (en) | 2003-02-17 | 2004-08-18 | Isis Innovation | Method and compositions for boosting immune response |
| US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
| US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
| BRPI0411099A (pt) | 2003-06-05 | 2006-07-18 | Wyeth Corp | composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus |
| US7291498B2 (en) | 2003-06-20 | 2007-11-06 | The Trustees Of The University Of Pennsylvania | Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US8119336B2 (en) | 2004-03-03 | 2012-02-21 | Ibis Biosciences, Inc. | Compositions for use in identification of alphaviruses |
| US20050221414A1 (en) | 2004-03-31 | 2005-10-06 | Katalin Varadi | Kit for measuring the thrombin generation in a sample of a patient's blood or plasma |
| US9024001B2 (en) | 2004-05-25 | 2015-05-05 | Novartis Vaccines And Diagnostics, Inc. | Alphavirus replicon packaging constructs |
| US20060198854A1 (en) | 2004-12-28 | 2006-09-07 | Peter Pushko | Vector platforms derived from the alphavirus vaccines |
| KR20130114758A (ko) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Ｍｉ-ｒｎａ를 포함하는 유전자 벡터 |
| ES2735531T3 (es) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
| WO2007047749A1 (fr) | 2005-10-18 | 2007-04-26 | Novartis Vaccines And Diagnostics Inc. | Immunisations mucosiques et systemiques avec particules de replicon d’alphavirus |
| WO2007056352A2 (fr) * | 2005-11-07 | 2007-05-18 | The Scripps Research Institute | Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire |
| JP5538729B2 (ja) | 2006-02-27 | 2014-07-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 偽感染性フラビウイルスおよびそれらの使用 |
| US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| GB0706914D0 (en) | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| CA2687141C (fr) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions et procedes pour produire des proteines de fusion bioactives |
| EP2167137B1 (fr) | 2007-05-31 | 2013-10-16 | GENimmune N.V. | Polyépitopes recombinants du vhp et utilisations |
| WO2009034190A2 (fr) | 2007-09-14 | 2009-03-19 | Genimmune N.V. | Marqueur d'affinité |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| GB0719526D0 (en) | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
| US20100285050A1 (en) | 2007-10-05 | 2010-11-11 | Isis Innovation Limited | Compositions and Methods |
| US9234181B2 (en) | 2007-11-26 | 2016-01-12 | Novartis Ag | RNA expression cassette and cells for making alphavirus particles |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| US20090253184A1 (en) | 2008-01-23 | 2009-10-08 | Introgen Therapeutics, Inc. | Compositions and methods related to an adenoviral trans-complementing cell line |
| WO2010005704A2 (fr) | 2008-06-13 | 2010-01-14 | New York University | Nouveaux vecteurs viraux sindbis défectueux, à plasmide assistant, et leurs procédés d'utilisation |
| EP2310510B1 (fr) | 2008-07-17 | 2015-05-06 | Medigen, Inc. | Vaccins à adni et procédés pour leur utilisation |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| CN102666582B (zh) | 2009-12-22 | 2016-03-30 | 弗·哈夫曼-拉罗切有限公司 | 序列依赖性聚集 |
| US9101572B2 (en) | 2009-12-31 | 2015-08-11 | Medigen, Inc. | Infectious DNA vaccines against chikungunya virus |
| GB201006405D0 (en) | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| KR102095670B1 (ko) | 2010-05-14 | 2020-03-31 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| NO2582728T3 (fr) | 2010-06-15 | 2018-01-20 | ||
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| JP6025721B2 (ja) | 2010-07-06 | 2016-11-16 | ノバルティス アーゲー | カチオン性水中油型エマルジョン |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| RS63817B1 (sr) | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
| EP2590626B1 (fr) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes à lipides ayant une valeur de pka avantageuse pour la délivrance d'arn |
| WO2012006369A2 (fr) | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation de grands mammifères à l'aide de faibles doses d'arn |
| DK3243526T3 (da) | 2010-07-06 | 2020-02-17 | Glaxosmithkline Biologicals Sa | Levering af rna til at udløse flere immunsignalveje |
| CN105734678B (zh) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
| BR112013004865A2 (pt) | 2010-08-31 | 2016-06-07 | Novartis Ag | lípidos adequados para entrega lipossomal de codificadores de proteínas rna |
| EP4119155A1 (fr) | 2010-08-31 | 2023-01-18 | GlaxoSmithKline Biologicals S.A. | Liposomes pegylés pour la délivrance d'arn codant pour un immunogène |
| PL2611467T3 (pl) | 2010-08-31 | 2022-08-16 | Glaxosmithkline Biologicals Sa | Małe liposomy do dostarczania rna kodującego immunogen |
| US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| US8722044B2 (en) * | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
| CA2835644C (fr) | 2011-05-13 | 2021-06-15 | Novartis Ag | Antigenes de pre-fusion f du vrs |
| SI3892295T1 (sl) | 2011-05-24 | 2023-09-29 | BioNTech SE | Individualizirana cepiva proti raku |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| WO2012171541A1 (fr) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Protéines hybrides humaines comportant des interférons et des protéines hétérodimériques modifiées par ubiquitine |
| JP2014520806A (ja) | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Ｒｎａ分子の送達のための有用なｎ：ｐ比を有するリポソーム |
| ES2702318T3 (es) | 2011-07-06 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| CA2840989A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Compositions de combinaisons immunogenes et utilisations de celles-ci |
| CA2841047A1 (fr) | 2011-07-06 | 2013-01-10 | Novartis Ag | Compositions immunogenes et leurs utilisations |
| US8859507B2 (en) | 2011-08-16 | 2014-10-14 | Samsung Electronics Co., Ltd. | Protein complex for intracellular delivery and uses thereof |
| MX366055B (es) | 2011-08-31 | 2019-06-26 | Novartis Ag | Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno. |
| AU2012322704B2 (en) | 2011-10-11 | 2017-09-07 | Novartis Ag | Recombinant self-replicating polycistronic RNA molecules |
| NZ628206A (en) | 2012-02-16 | 2016-03-31 | Vlp Therapeutics Llc | Virus like particle composition |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US20160289674A1 (en) | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| SG10201609511XA (en) | 2012-05-18 | 2016-12-29 | Univ Pennsylvania | Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof |
| EP2870236B1 (fr) | 2012-07-04 | 2018-01-10 | Sirion Biotech GmbH | Supports et procédés pour accroître la production d'adénovirus |
| CN104853770A (zh) | 2012-07-06 | 2015-08-19 | 诺华股份有限公司 | 免疫原性组合物及其应用 |
| EP2759570B1 (fr) | 2012-10-11 | 2016-01-13 | LG Chem, Ltd. | Copolymère acrylate d'alkyle-composé aromatique vinylique-composé cyanure de vinyle ayant une résistance à l'impact à basse température améliorée, et composition de polycarbonate le comprenant |
| GB201220119D0 (en) | 2012-11-08 | 2012-12-26 | Univ Cork | Vector |
| EP2991679A4 (fr) | 2013-04-29 | 2016-12-07 | Adimab Llc | Réactifs multispécificité, procédés de préparation et d'utilisation associés |
| JP6734651B2 (ja) | 2013-06-03 | 2020-08-05 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | マラリアワクチン |
| BR112016008806A2 (pt) | 2013-11-01 | 2017-10-03 | Pfizer | Vetores para expressão de antígenos associados à próstata |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| WO2015075201A1 (fr) | 2013-11-21 | 2015-05-28 | Genmab A/S | Formulation lyophilisée de conjugués anticorps-médicaments |
| JP5957637B2 (ja) * | 2014-02-03 | 2016-07-27 | 国立研究開発法人国立がん研究センター | 抗ＴｉｓｓｕｅＦａｃｔｏｒモノクローナル抗体 |
| EP4029873A1 (fr) | 2014-09-17 | 2022-07-20 | Zymeworks Inc. | Composés cytotoxiques et antimitotiques et leurs procédés d'utilisation |
| US20180030140A1 (en) | 2015-02-06 | 2018-02-01 | Navigo Proteins Gmbh | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments |
| PL3280441T3 (pl) | 2015-04-07 | 2022-02-21 | Alector Llc | Przeciwciała przeciwko sortilinie i sposoby ich stosowania |
| US20190030178A1 (en) | 2015-09-11 | 2019-01-31 | Genmab A/S | Dosing regimens for anti-tf-antibody drug-conjugates |
| PE20181535A1 (es) | 2015-12-16 | 2018-09-26 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno |
| SG11201909652WA (en) | 2017-04-19 | 2019-11-28 | Gritstone Oncology Inc | Neoantigen identification, manufacture, and use |
| CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| CN111727075B (zh) | 2017-11-27 | 2024-04-05 | 普渡制药公司 | 靶向人组织因子的人源化抗体 |
| CN111818943A (zh) | 2018-01-04 | 2020-10-23 | 伊科尼克治疗公司 | 抗组织因子抗体、抗体-药物缀合物及相关方法 |
-
2019
- 2019-01-04 CN CN201980016636.6A patent/CN111818943A/zh active Pending
- 2019-01-04 KR KR1020207022435A patent/KR20200118029A/ko active Search and Examination
- 2019-01-04 BR BR112020013679-4A patent/BR112020013679A2/pt unknown
- 2019-01-04 US US16/959,652 patent/US20220153871A1/en active Pending
- 2019-01-04 SG SG11202006400UA patent/SG11202006400UA/en unknown
- 2019-01-04 MX MX2020007077A patent/MX2020007077A/es unknown
- 2019-01-04 AU AU2019205330A patent/AU2019205330A1/en active Pending
- 2019-01-04 WO PCT/US2019/012427 patent/WO2019136309A1/fr unknown
- 2019-01-04 EP EP19735874.0A patent/EP3735271A4/fr active Pending
- 2019-01-04 JP JP2020557125A patent/JP2021509823A/ja active Pending
- 2019-01-04 CA CA3087537A patent/CA3087537A1/fr active Pending
-
2020
- 2020-06-30 IL IL275765A patent/IL275765A/en unknown
- 2020-07-02 PH PH12020551037A patent/PH12020551037A1/en unknown
-
2021
- 2021-08-26 US US17/458,507 patent/US11447566B2/en active Active
-
2022
- 2022-07-29 US US17/877,853 patent/US20230159657A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110621A patent/JP2023134565A/ja active Pending
- 2023-09-01 JP JP2023142243A patent/JP2023175726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3625259B1 (fr) | Anticorps anti-sirpalpha | |
| BR112020013679A2 (pt) | anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados | |
| CN106459200B (zh) | 抗-egfr抗体及抗体药物偶联物 | |
| AU2013370548B2 (en) | Prolactin receptor binding proteins and uses thereof | |
| EP2493929B1 (fr) | Anticorps anti-egfr et leurs utilisations | |
| KR101572171B1 (ko) | 톨-유사 수용체 2에 대한 인간화 항체 및 이의 용도 | |
| CN115698079A (zh) | 抗cd79b抗体药物偶联物、其制备方法及其医药用途 | |
| CA3066918A1 (fr) | Anticorps anti-il1rap et conjugues anticorps-medicament | |
| US11981732B2 (en) | Anti-TMEFF1 antibodies and antibody drug conjugates | |
| BRPI0714873A2 (pt) | antagonistas de receptor-1 ativado por protease (par-1) | |
| JP6931750B2 (ja) | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 | |
| CN112996809A (zh) | 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途 | |
| EA036927B1 (ru) | Конъюгированные антитела против ly75 для лечения рака | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| CN114828887A (zh) | 抗-αVβ6抗体和抗体-药物偶联物 | |
| JPWO2019136309A5 (fr) | ||
| BR112020026724A2 (pt) | Proteína de ligação ao antígeno anti-steap1 | |
| US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas | |
| US11390685B2 (en) | ErbB2 antibodies and uses therefore | |
| JP2020508694A5 (fr) | ||
| TW202317630A (zh) | 抗gfral抗體及其應用 | |
| WO2024023273A1 (fr) | Molécules bispécifiques de liaison à l'antigène anti-c-kit et anti-cd203c et leurs utilisations | |
| JP2024526428A (ja) | ヒトインターロイキン－４受容体アルファ抗体グルココルチコイドコンジュゲート | |
| TW202412854A (zh) | 人類介白素-4-受體α抗體醣皮質激素結合物 | |
| TW202221029A (zh) | 抗cd93之構築體及其用途 |